Henagliflozin - Jiangsu HengRui MedicineAlternative Names: SHR-3824
Latest Information Update: 07 Nov 2017
Price : *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Glucosides
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 01 Nov 2017 Jiangsu HengRui Medicine plans a phase I drug interaction trial for Type 2 diabetes mellitus (In volunteers) (PO) (NCT03329118)
- 22 May 2017 Jiangsu HengRui Medicine plans a phase III trial for Type-2 diabetes mellitus (Monotherapy) in China (NCT03159052)
- 15 Dec 2016 Biomarkers information updated